The Government has put in place a Uniform Code for Pharmaceutical Marketing Practices (UCPMP) for Pharmaceutical companies, which is in operation since 01.01.2015, to prevent unethical practices by pharmaceutical companies. This code governs the conduct of pharmaceutical companies in their marketing practices, duly covering various aspects such as medical representatives, textual and audio-visual promotional materials, samples, gifts, etc. Further, the code establishes relationships with healthcare professionals, wherein the provisions related to travel facilities, hospitality, and cash or monetary grants to physicians or their families have been elaborated. The code also details the mode of operation of the code, the responsibilities of the Pharmaceutical Associations in constituting the Ethics Committee for Pharmaceutical Marketing Practices (ECPMP) for handling the complaints and the Apex Ethics Committee for Pharmaceutical Marketing Practices (AECPMP) for review, the procedure of lodging a complaint, procedure of handling of complaints by the Pharmaceutical Associations and various penalty provisions.
The code has been adopted by all the major associations of pharmaceutical companies and the Department in various instances has reviewed the implementation of the code by the Pharmaceutical associations. The complaints of violation of the voluntary UCPMP by pharma companies, as received by the Department, are forwarded to the concerned pharmaceutical associations for taking necessary action.
Besides UCPMP, there exists sufficient and enforceable legal regime to counter, control, and dis-incentivize unethical marketing practices such as “Indian Medical Council Professional Conduct, Etiquette and Ethics) Regulations, 2002” under the Indian Medical Council Act, 1956, provisions available under Income Tax Act, Drugs and Cosmetics Act, Prevention of Corruption Act, etc
As per information received from the Central Drugs Standard Control Organisation (CDSCO) under the Ministry of Health & Family Welfare that the manufacture, sale, and distribution of drugs in the country are regulated under the provisions of the Drugs & Cosmetics Act, 1940 and Rules thereunder through a system of licensing and inspection. Licenses for the manufacture, sale, and distribution of drugs are granted by the State Licensing Authorities (SLAs) appointed by respective State Governments. Under the said Rules, Fixed Dose Combinations (FDC) are a New Drug. For the manufacture of any FDC falling under the definition of a New Drug, permission is required from Central Drugs Standard Control Organisation (CDSCO) before obtaining a manufacturing license for the New Drug from the concerned State Licensing Authority. Under the aforesaid Act, the manufacture/sale/distribution of any banned drug is a punishable offense. State Licensing Authorities are empowered to take action in this regard.
Some cases of granting of manufacturing licenses of new drugs including Fixed Dose Combinations (FDCs) by some of the State Licensing Authorities (SLAs) without due approval of the Drugs Controller General (India) [DCG (I)] came to the notice of the Government. Apart from issuing repeated statutory directions under Section 33P of the Drugs & Cosmetics Act, 1940 to the State Governments not to issue such licenses to FDCs falling under the definition of new Drugs without the approval of DCG(I), the Central Government constituted an Expert Committee under the chairmanship of Prof C.K. Kokate to examine the safety and efficacy of such FDCs.
Based on the recommendations of the Prof. C. K. Kokate Expert Committee, the Central Government prohibited 344 FDCs vide notification dated 10.03.2016. Further, the Central Government also prohibited 5 FDCs vide notification dated 08.06.2017.
However, with respect to the prohibition of the said 344 FDCs, several writ petitions were filed in different High Courts across the country challenging the ban of the FDCs. After that, the Hon’ble High Court of Delhi vides its order dated 01.12.2016 and quashed the said notification. The Union of India challenged the said order of the Hon’ble Delhi High Court before the Hon’ble Supreme Court by way of filing a Special Leave Petition (SLP). Further, about 20 cases against 5 FDCs prohibited on 08.06.2017 which were pending before various High Courts across the country, were also transferred to Supreme Court. Hon’ble Supreme Court, vide its order dated 15.12.2017, directed that an analysis be made in greater depth and that these cases of (344+5) FDCs should go to the Drugs Technical Advisory Board (DTAB) and/or a Sub-Committee formed by the DTAB for the purpose of having a relook into these cases.
Accordingly, a Sub-Committee of DTAB was constituted which after providing a hearing to all the petitioners/appellants, submitted its report to DTAB which was accepted by DTAB. Based on the recommendations of DTAB, the Central Government, vide notifications dated 07.09.2018, prohibited 328 FDCs for manufacture, sale, or distribution. The Government also restricted 06 FDCs for manufacture, sale, or distribution with certain conditions vide notifications issued on the same date. However, various firms/stakeholders have filed writ petitions in various High Courts across the country including the Hon’ble Supreme Court against the said notifications dated 07.09.2018.
Earlier, in 2007, CDSCO had received complaints from consumer associations regarding the rationality of certain Fixed Dose Combinations (FDC) marketed in the country. As a follow-up action, CDSCO prepared a list of 294 FDCs and communicated to State Drugs Controllers vide letter dated 14.08.2007. A writ petition was filed in the Hon’ble High Court of Madras and the Hon’ble Court granted a stay order. However, DTAB in its meeting held on 16.1.2008 constituted a sub-committee to examine these FDCs. The recommendation of the subcommittee was referred to the Hon’ble Supreme Court. The Hon’ble Supreme Court in its judgment, dated 15.12.2017, accepted the recommendations of DTAB and ordered for disposal of these petitions. Accordingly, Central Government vide notifications S.O. 180(E) to S.O.259 (E), dated 11.01.2019, prohibited 80 FDCs from the manufacture, sale, or distribution.Disclaimer: We donot claim that the images used as part of the news published are always owned by us. From time to time, we use images sourced as part of news or any related images or representations. Kindly take a look at our image usage policy on how we select the image that are used as part of the news.